By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

KAEL–GemVax 

912-18 Daechi-Dong
2nd Floor Lia B/D
Gangnam  Seoul    Korea
Phone: 82-2-544-6221 Fax: 82-2-3443-4997


SEARCH JOBS


Industry
Pharmaceutical






Company News
KAEL–GemVax Release: Final Results From the Phase III TeloVac Trial in Pancreatic Cancer Presented at American Society of Clinical Oncology, Chicago, June 3rd 2013. 6/3/2013 11:08:09 AM
KAEL–GemVax Reports Encouraging Interim Progress in Phase II Study of GV1001 Anti-telomerase Vaccine in NSCLC 11/15/2011 6:27:23 AM
KAEL–GemVax: TeloVac Becomes World’s Largest Ever Pancreatic Cancer Vaccine Trial 5/5/2011 10:58:54 AM
Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy 12/6/2010 11:50:35 AM
KAEL–GemVax Reports Significant Interim Progress In UK Telovac Phase III Study Of GV1001 Anti-Telomerase Vaccine In Pancreatic Cancer 7/12/2010 10:47:47 AM
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy 6/8/2010 10:54:48 AM
//-->